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Store-operated calcium entryCalcium ions have important roles in cellular processes including intracellular signaling, protein folding, enzyme
activation and initiation of programmed cell death. Cellsmaintain low levels of calcium in their cytosol in order to
regulate these processes. When activation of calcium-dependent processes is needed, cells can release calcium
stored in the endoplasmic reticulum (ER) into the cytosol to initiate the processes. This can also initiate activation
of plasma membrane channels that allow entry of additional calcium from the extracellular milieu. The change
in calcium levels is referred to as calcium ﬂux. A key protein involved in initiation of calcium ﬂux is Stromal
Interaction Molecule 1 (STIM1), which has recently been identiﬁed as a sensor of ER calcium levels. STIM1 is
an ER transmembrane protein that is activated by a drop in ER calcium levels. Upon activation, STIM1 interacts
with a plasma membrane protein, ORAI1, to activate ORAI-containing calcium-selective plasma membrane
channels. Dysregulation of calcium ﬂux has been reported in cancers, autoimmune diseases and other diseases.
STIM1 is a promising target in drug discovery due to its key role early in calciumﬂux. Herewe review the involve-
ment and importance of STIM1 in diseases andwhy STIM1 is a viable target for drug discovery. This article is part
of a Special Issue entitled: Calcium signaling in health and disease. Guest Editors: Geert Bultynck, Jacques Haiech,
Claus W. Heizmann, Joachim Krebs, and Marc Moreau.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Calcium (Ca2+) and magnesium (Mg2+) ions are useful ubiquitous
ions in biology. They both have an oxidation state of +2 which gives
them greater strength in interacting with anionic complexes compared
to sodium, potassium or other monocations. Therefore, Ca2+ andMg2+
ﬁll important roles in processes that require control of larger molecules
such as protein folding (Ca2+) and coordinating ATP (Mg2+). Ca2+ and
Mg2+ have evolved into different functions in cells, sometimes counter-
ing each other. Mg2+ is the eleventh most abundant element in the
body and interacts with phosphates in DNA, RNA, ATP and other
phosphate-containingmolecules, enhancing themobility and ﬂexibility
of themolecules by countering their anionic charges. Therefore,Mg2+ is
routinely more ubiquitous in the cell. Ca2+, on the other hand, is the
ﬁfth most abundant element in the body but 99% of it is sequestered
in bone. Among the roles for Ca2+, a major role is acting as a secondary
signal to convert signals from the extracellular environment into speciﬁc
intracellular responses. Also, Ca2+ is involved in the rapid depolarization
of cells in neurons and muscle cells. These actions need to be tightlysignaling in health and disease.
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.controlled. Therefore, Ca2+ is kept at low levels in the cell's cytosol
until needed.However, in order to rapidly respondwhenCa2+ is needed,
Ca2+ is stored in the endoplasmic reticulum (ER) and mitochondria for
quick release that initiates Ca2+ dependent actions.2. Calcium ﬂux
2.1. Calcium dependent processes
Calcium ions play vital roles in a variety of important physiological
functions of the cell, including control of cell cycle progression, cell
differentiation, mitosis, apoptosis, ETosis, cell mobility, macrophage
activation, chromatin packaging & modiﬁcations, protein folding and
control of potassium & calcium channels. Often Ca2+ is serving as a
secondary messenger, conveying an external signal received through
ligand/receptor binding, into speciﬁc responses within the cell. Several
of these roles of Ca2+ can be exempliﬁed by human peptidyl arginine
deiminase 4 (PAD4), a calcium-dependent enzyme. PAD4 is inactive
until it binds Ca2+ (enzyme activation). The structures of inactive
PAD4 and active PAD4 have been published (shown in Fig. 1) [1].
Comparison of inactive PAD4 and active PAD4 shows stabilization of
residues including around the active site (protein folding) [Fig. 1].
When active, PAD4 can convert arginine residues to citrulline, such as
in histones [Fig. 2] [2]. This reduces the histone–DNA interactions and
alters chromatin for gene activation or permanently alters chromatin
Fig. 1. Peptidyl arginine deiminase 4. A) Structure of PAD4without calcium ions (based on X-ray data in 1WD8.pdb [1]). B) Structure of PAD4with calcium ions, shown as 5 pink spheres
(based on X-ray data in 1WD9.pdb [1]). Comparing the close-up views (at right) of A & B, note how calcium ions associate with stabilization of: (*1) residues near the active site; (*2) a
short stretch of alpha helix; (*3), and a loop of residues.When calcium ions are not present (A), the residues at these sites are too randomlydistributed to determine speciﬁc 3D coordinates
and, therefore, they do not appear in the ﬁnal pdb ﬁle.
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ETosis) [3,4].2.2. Calcium storage and release
PAD4 involvement in apoptosis demonstrates a critical need for
control of intracellular Ca2+ in order to prevent inappropriate activation
of calcium-dependent processes. To prevent such aberrant events, the
available Ca2+ is kept at approximately 100 nM in the cytosol, whereas
in the extracellular environment, Ca2+ is typically at 1 mM or greater.
Regulation of intracellular Ca2+ involves: 1) Ca2+ release from intracel-
lular organelles, such as the ER and mitochondria, 2) Ca2+ entry from
the extracellular environment, and 3) reestablishment of stored Ca2+
levels and lower cytosolic Ca2+. These processes are referred to asFig. 2. Deimination reaction of PAD4. PAD4 can convert peptidyl arginine residues to
citrulline in proteins, such as histones. Deimination, also referred to as citrullination,
reduces the positive charge of arginine to a neutral citrulline. In the case of histones, this
can loosen their interactionswithDNA. PAD4 can also convertmethylated arginine residues
and PAD4 can undergo self-deimination, potentially inactivating itself [2].calcium ﬂux. One process that can connect stored Ca2+ release and ex-
tracellular Ca2+ entry is called store-operated calcium entry (SOCE) [5].
In SOCE an initial event, such as a ligand binding to a receptor, triggers
release of stored Ca2+ from the ER. One example is when a G protein-
coupled receptor (GPCR) binds its ligandwhich activates phospholipase
C (PLC) to convert phosphatidyl inositol 4,5-bisphosphate (PIP2) to
inositol 1,4,5-trisphosphate (IP3). IP3 then traverses through the cytosol
to the ER membrane surface where it activates the IP3 receptor (IP3R).
The IP3R receptor is a family of ER transmembrane proteins (IP3R
types I, II and III) that, upon activation, can open as a channel to release
Ca2+ into the cytosol [6,7]. Another family of ER transmembrane pro-
teins, the ryanodine receptor (RyR-1, RyR-2), is also a Ca2+ channel
for release of ER stored Ca2+ [8,9]. Both IP3R and RyR are strongly biased
towards Ca2+ release as opposed to monocations. IP3R is the dominant
responder when ER Ca2+ release is needed. The PLC activation that
results in IP3 which activates IP3R can begin from a number of different
plasma membrane receptors but GPCRs, with their great variety of
sequences and ligands, are very frequently the initiators. RyRs, on the
other hand, respond to Ca2+, such as inﬂow of extracellular Ca2+,
which activates RyR opening to release ER stored Ca2+. The actual acti-
vation of the IP3R and RyR channels is dependent on spatial and tempo-
ral differences in the Ca2+ ﬂow and concentrations. For example, within
the ER lumen, Ca2+ aids in the folding of nascent proteins that are des-
tined for extracellular exposure and, therefore, there is a focus of Ca2+
in the ER lumen at those sites where signal recognition particle (SRP)
receptors are docked with actively translating ribosomes. The spatial
and temporal differences in Ca2+ are often referred to aswaves or oscil-
lations and the intensity and persistence of the wave can impact the
strength and duration of the activity of ER Ca2+ channels which then
impact the cytosolic and nuclear Ca2+-dependent activities. Cytosolic
Ca2+ can affect the ER Ca2+ release channels but, as research continues,
we are learning that some proteins can also inﬂuence the channels,
giving further complexity to the secondary messenger activity of Ca2+
[10]. Another purported ER Ca2+ release channel is presenilin (PS).
This is a family (PS-1, PS-2) of multi-pass ER transmembrane proteins
that is purported to coordinate the expression, induction and activity
of IP3R and RyR channels in order to control Ca2+ homeostasis [11]. PS
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tion. In addition, PS has been proposed as a means of controlling the
activity of the smooth ER calcium ATPase (SERCA) channel that pumps
Ca2+ into the ER in an energy-dependent process that restores the ER
Ca2+ levels in preparation for the next round of Ca2+ release. And so
PS may control and coordinate the activities of IP3R, RyR and SERCA to
maintain Ca2+ homeostasis in the ER. PS is referred to as a slow leak
Ca2+ channel since it can allow some Ca2+ movement as it continually
ﬁne-tunes Ca2+ in the ER.
2.3. Entry of extracellular Ca2+
Cells have several types of channels that are Ca2+ permeable and, in
some cases, Ca2+ selective. Among these channels are: voltage gated
channels, transient receptor potential (TRP) channels, and the ORAI
channels. The voltage-gated Ca2+ channels are a diverse group of
multi-subunit transmembrane proteins that react to cell membrane
depolarization and facilitate calcium inﬂux [12]. These are primarily
found in excitable cells such as neurons. Much of the difference in
activity of these channels relates to the combinations of subunits incor-
porated into a particular voltage-gated Ca2+ channel. For example, the
transmembrane α1 subunit has at least 10 different analogs. These
subunits can dictate the selectivity and rate of Ca2+ entry. The cytosolic
β subunits can affect the duration of channel opening. Both theα1 andβ
subunits can be regulated by phosphorylation.
The TRP channels are members of the super family of transient
receptor potential channels (subfamilies: TRPC, TRPV, TRPM, TRPA,
TRPP, TRPML) that are, in general, Ca2+ permeable but they can also
facilitate movement of Na+ [13]. Similar TRPs are found across many
species and mammals have TRPs from each of the subfamilies except
TRPN. These channels can react to a broad range of stimuli including,
in the case of the TRPV subfamily, thermal changes. The stimuli can
act directly by ligand activation from binding of small molecules
(ex. capsaicin) or indirectly by PLC that has been activated by receptor
tyrosine kinases [13]. As an example of the TRP subfamilies, in the
TRPV channels, TRPV5 (found primarily in kidney cells) and TRPV6
(found primarily in the small intestines and to a lesser extent in the
esophagus, colon, prostate, and placenta) are the most Ca2+ selective
members of the TRPV family. Expression of TRPV5 and TRPV6 is upreg-
ulated by vitamin D [14]. There are multiple means of regulating TRPV5
and TRPV6 by both extracellular calcitropic factors (such as increased
TRPV5 activity due to Klotho, tissue kallikrein and/or changes in pH in
pro-urine) and intracellular factors (such as endosomal recycling to
the cell surface of sequestered TRPV5 to increase active TRPV5) [15,16].
The ORAI channels are highly selective for Ca2+ entry and bring
a different approach to initiation of calcium ﬂux. Activation of ORAI
channels by STIM requires localization of STIM to the puncta, the region
of the ER closest to the plasmamembrane, and interaction of STIMwith
ORAI molecules. The activated ORAI channels consist of two main
components: 1) the stromal interaction molecules (STIM) which are
found primarily in the ER membrane as single pass transmembrane
proteins and 2) the ORAI molecules which are found in the plasma
membrane as multi-pass transmembrane proteins.
3. STIM/ORAI interactions
3.1. CRAC channel activation
The STIM molecules are most important in the activation of ORAI
channels since STIM senses decreases in Ca2+ in the ER lumen.Whereas
PAD4 [mentioned above and Fig. 1] becomes active when it binds ﬁve
calcium ions, STIM is in an inactive state with a bound calcium ion,
and becomes active when ER stored Ca2+ drops, resulting in loss of
the bound calcium ion in STIM. This change to active STIM [described
in Fig. 3] allows for conformational changes that facilitate STIM dimer-
ization and lateral migration in the ER membrane to the puncta, closeto the plasma membrane. During this process, STIM interacts with
ORAI molecules and, with this formation of interactions between STIM
and ORAI, the ORAI pore-forming molecules are able to become an
active open channel selective for Ca2+ entry from the extracellular mi-
lieu [Fig. 4]. This channel complex is called a calcium release activated
calcium (CRAC) channel and demonstrates the basic concept in SOCE.
We now know that SOCE activity can be initiated by threemechanisms:
1) activation of IP3 receptors in the ER membrane, 2) blocking SERCA
pumps in the ER membrane (ex. thapsigargin is a SERCA inhibitor) or
3) Ca2+ ionophores that permeabilize the ER membrane.3.2. STIM1 and STIM2
The known STIM proteins, STIM1 (685 residues and maps to chro-
mosome 11p15.5) and STIM2 (746 residues and maps to chromosome
4p15.1), are homologous structures that share the same genomic struc-
ture, organization of protein domains, and biochemical features. STIM1
and STIM2 have 53% amino acid identity and high sequence similarity
(N65%) [17], including the composition of the ER luminal Ca2+-
sensing domains responsible for STIM dimerization and activation
of ORAI channels [18–23]. But there are still differences in the way
STIM1 and STIM2 work as Ca2+ sensors and activators of SOCE. For
example, the Ca2+-binding domains are identical except for three
residues, but STIM1 is twice as sensitive to Ca2+ changes in the ER com-
pared to STIM2 [19]. The corresponding ER luminal structures of STIM1
and STIM2 have been determined for residues 58–201 and 62–205,
respectively, but the placements, and more importantly, the functions
of themissing residues are yet to be determined [24–28]. These missing
residues may have roles in securing the bound calcium ion and/or
anchoring of the STIM protein. These may have an effect on the Ca2+
sensitivity.Whether or not these residues are involved in the overall re-
sponse, as it is, STIM2 is considered to be a slow responder to ER luminal
Ca2+ changes compared to STIM1. There are also differences in STIM1
and STIM2 in the furthest portions of the C-terminal end in the cytosolic
portions of the proteins. These are sites containing much of the STIM/
ORAI interactions and these differences could inﬂuence the speed and
strength of ORAI channel activation. Inmost cells, STIM1 is predominant
in mediating activation of SOCE, believed to be due in part to STIM1's
greater Ca2+ sensitivity whereas STIM2 blocks SOCE if overexpressed,
possibly due to STIM1/STIM2 interactions that compete with STIM1
homodimerization upon activation [17]. Knockdown of STIM2 in most
cell types has little to no effect on SOCE but, in neurons and dendritic
cells, STIM2 appears to be the predominant mediator of SOCE [17]. Spa-
tial and temporal differences in STIM1 and STIM2 activation suggest
that STIM2 is theweaker activator of ORAI channels. Further knowledge
of STIM2 is needed to understand its involvement but, as it is, STIM1 has
been deemed more important in activation of SOCE and as a partner of
ORAI proteins in non-excitable cells. The full extent of STIM effects on
calcium ﬂux is still under intense research since their inﬂuence goes
beyond ORAI channels. Among the Ca2+ channels, STIM1 has been
most closely associated with ORAI channels. However, STIM1 also inﬂu-
ences someof the TRPC channels and, thereby, brings the TRPC channels
into the realm of SOCE or suggesting roles for STIM1 independent
of SOCE [29]. It is these multiple roles for STIM (STIM1 and STIM2) in
calcium ﬂux, along with the fact that STIM activation is one of the
early and focal points in SOCE initiation that makes STIM important as
a potential therapeutic target in calcium dysregulation diseases.
Indeed, there have been a number of calcium dysregulation diseases
identiﬁed in which STIM1 is a suspect due to underexpression, overex-
pression or mutations of STIM1.Wewill next discuss some of themajor
diseases that have shown calcium dysregulation and possible STIM in-
volvement. Other recent reviews provide additional insights into the in-
volvement of SOCE, STIMs and ORAI channels in diseases and abnormal
states as well as current understanding of the mechanisms and interac-
tions [30–33].
Fig. 3. STIM1 activation schematic. Human STIM1 is a single pass transmembrane protein resident in the ERmembrane. STIM1 has an ER luminal portion containing the EF-hand and SAM
(sterile αmotif) domains. STIM1 also has a cytosolic portion, SOAR (STIM1–ORAI1 activation region) also referred to as CAD (CRAC channel activation domain). The EF-hand domain is a
calcium-bindingmotif frequently found in calcium binding proteins, such as calmodulin with four such sites. Loss of the bound calcium ion leads to conformational changes that are con-
veyed into the SAMdomain, amotif frequently found inprotein–protein interactions. The active STIMcan then homodimerizewith other STIMmoleculeswith interactions primarily in the
ER luminal portions. Loss of the calcium ion also leads to conformational changes in the cytosolic portion of STIM. This opens the SOAR to expose the coiled-coil regions (C1, C2, C3) and
extends theproline/serine-rich and lysine-rich regions out into the cytosolwhere interactionswithORAImolecules can occur. This cartoondepicts howSTIM1maychangewhen activated,
based roughly on [25] the published structures of inactive STIM1 SOAR (3TEQ.pdb) [26] and ER lumen domains (2K60.pdb) [27].
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We will discuss SOCE involvement, particularly in relation to STIMs,
in somemajor diseases: Alzheimer's disease, cancers and immunological
diseases. Additional diseases and their relation to STIMs are listed in
Table 1, but it is not an exhaustive list. We can expect that other diseases
will be found in the future to have Ca2+ dysregulation that involves
STIMs and SOCE.
4.1. Alzheimer's disease
Alzheimer's disease (AD) is a chronic neurodegenerative disorder
that destroys neurons and causes synapse loss in the hippocampus and
cortex which can result in cognitive disorders and dementia. The events
leading to AD involve an accumulation of β-amyloid peptide (Aβ)
in plaques which leads to neuron perturbations and eventually
degeneration. The Aβ is generated by cleavage of a membrane protein,
β-amyloid precursor protein (APP), by β-secretase and γ-secretase.
Accumulation of Aβ on neurons can induce oxidative stress which then
disrupts intracellular Ca2+ homeostasis [34]. The role of Ca2+ in AD
pathogenesis has been discussed previously [35–39]. Since we are con-
tinually gaining more knowledge of STIMs in normal calcium ﬂux, we
can now consider how STIMs could be useful targets in AD therapeutics.
Neuron degeneration in AD is affected by disturbances in the Ca2+ ho-
meostasis in the ER. This is attributed to mutations in the presenilin-1
(PS1) gene in some cases of early onset inherited AD (familial AD, FAD)
[34]. More than 100 different mutations have been identiﬁed in PS1 inrelation to FAD. Besides regulating ER Ca2+, PS1 is an aspartyl protease
that, as part of the γ-secretase complex, cleaves the APP to produce Aβ.
The excessive activity of mutated PS1 in APP cleavage, its impact on
IP3R and RyR channels in ER Ca2+ release and the resulting oxidative
stress from neuron dysregulation can lead to disruption of intracellular
Ca2+ homeostasis. In fact, increased intracellular Ca2+ and increased du-
ration of IP3R opening have been reported for mutated PS1 in FAD [40].
And as was noted previously, PS1 can increase expression of STIM1 and
STIM2. STIMswould be involved by sensing the ERCa2+ changes and ini-
tiating ORAI and TRP channel activity. In addition, in neurons there are
the voltage-dependent Ca2+ channels (VDCC) and NMDA-type gluta-
mate receptors (NMDAR) that have a role in Ca2+ entry. The effect of
mutant PS1 is to generate ‘sparks’ of intracellular Ca2+ that disturb nor-
mal Ca2+ dependent processes [34]. Elevated intracellular Ca2+ in pre-
synaptic axons can increase glutamate release which then can increase
Ca2+ entry in postsynaptic dendritic cells by stimulating glutamate re-
ceptors and NMDARs in the dendritic cells. Therefore, STIM, as an ER
Ca2+ sensor in both the presynaptic axons and postsynaptic dendritic
cells, is a potential target for amelioration of AD. We should remember
that, as mentioned previously, in neurons STIM2 appears to have a dom-
inant role whereas STIM1 is dominant in other cell types.
4.2. Cancers
Recent reviews of STIM involvement in cancers along with other
diseases are available [81,82]. Here we will touch on a few cancer
types as examples. In cancers, the disruption of Ca2+ homeostasis can
Fig. 4. Store operated calcium entry. (1) Ca2+ is stored in the ER through anATP-dependent pathway by a Smooth ER CalciumATPase (SERCA). (2)When a ligand binds a receptor, such as
a G-coupled protein receptor, phospholipase C (PLC) is activated and converts phosphatidyl inositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3)which activates release of
stored Ca2+ throughan IP3 receptor. (3) STIM1 senses the lowERCa2+ levels and (4) becomes active and (5) homodimerizes. (6) STIM1moves to thepuncta and oligomerizeswithORAI1
in the plasma membrane to activate CRAC (Calcium Release Activated Calcium) channels. (7) Extracellular Ca2+ enters to increase the cytosolic Ca2+ to effective levels. As the Ca2+-
dependent activity ﬁnishes, the ER is replenished with Ca2+ by the SERCA. Cartoon based roughly on [25] and [28].
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and cell migration/motility.
4.2.1. Colorectal cancer
Chronic inﬂammation is a driving force in development andprogres-
sion of colorectal cancer.
EGF has an important role in the metastasis that can occur. EGF-
mediated signals induce SOCE which, in turn, activates transcription
factors (such as CREB/NFAT) that invoke increased transcription of
genes [83]. In cases of colorectal cancer, allelic imbalances at chromosome
4p15 have been associated with tumor growth but no genes were identi-
ﬁed. STIM2 is located at locus 4p15.2 and previously it has been proposed
as a candidate gene in glioblastomamultiforme. Using xenograft analysis,
STIM2 overexpression in colorectal cancer was found to be a frequent
trait in colorectal cancer that results in suppression of cell growth [84].
It has been proposed that increased STIM2 may interfere with the
tumor suppressor effect of STIM1-mediated induction of apoptosis and,
as a result, tumor progression and metastasis occur.
4.2.2. Hepatocellular carcinoma
In hepatocellular carcinoma (HCC) cells, Ca2+ inﬂuxwas demonstrat-
ed to be involved in liver oncogenesis. STIM1 has been found to have a
higher expression in hepatoma tissues compared to precancerous tissues
of the same patients and compared to a normal hepatocyte cell line. HCC-
LM3 cells, which have a higher migration ability, expressed STIM1 at a
level ﬁve times higher than other HCC cell lines [42].4.2.3. Cervical cancer
STIM1-dependent signaling plays a vital role in cervical cancer cell
proliferation, migration, and angiogenesis. Overexpression of STIM1 in
tumor tissue is seen in 71% of cases with early-stage cervical cancer.
Cancer cell migration stimulated by EGF involves expression of STIM1
and EGF increases the interactions between STIM1 and ORAI1 in the
puncta, thereby inducing Ca2+ inﬂux [43]. Another study used SOCE in-
hibitors, SKF96365, 2-APB and YM-58483, and found that they inhibited
cervical cancer cellmigration akin to STIM1 silencing and STIM1 overex-
pression signiﬁcantly enhanced cervical cancer cell migration. STIM1
was found to play a role in controlling cell migration by regulating acto-
myosin [44].
4.2.4. Glioblastoma multiforme
The prognosis of glioblastoma multiforme (GBM) is poor and new
therapeutics are drastically needed. GBM [World Health Organization
classiﬁcation (WHO) grade IV astrocytoma] is the most frequent type
of brain tumor in adults. Themedian survival rarely exceeds 12 months
[48]. One study used real time PCR for gene expression analysis and
found 18 overexpressed proteins one of which was STIM1 [49]. Ca2+
entry in GBM tumor cell proliferation and survival was studied in
glioblastoma cell lines, C6 (rat) and U251 (human). It was seen that
ORAI1 and STIM1 expressions using siRNA signiﬁcantly inhibited C6
cell proliferation and SOCE compared to control cells, more signiﬁcantly
in cellswithORAI1 siRNAknockdown than in STIM1-treated cells show-
ing that Ca2+ entry via ORAI1 and CRAC channels is important for GBM
Table 1
Some diseases with possible STIM involvement.
Disease Issue Reference
Alzheimer's
Alzheimer's disease SOCE affects major enzymes [36,38,69–71]
Cancer related diseases
Melanoma Mutation of STIM1/ORAI1 [45]
Melanogenesis Overexpression of STIM2 [47]
Glioblastoma STIM1/ORAI1 overexpression [49–51,72]
Colorectal cancer Overexpression of STIM1 [74]
Neuroblastoma Overexpression of STIM1 [73]
Breast cancer ORAI/STIM2 expression,
STIM1 overexpression
[41,85,86]
Cervical cancer Overexpression of STIM2 [43,44]
Non-small cell lung cancer Overexpression of STIM1 [75]
Hepatocellular carcinoma Overexpression of STIM1 [42]
Prostate cancer Overexpression of STIM1 [76,77]
Renal cell cancer Overexpression of STIM1 [78]
Immunity related diseases
Severe immunodeﬁciency STIM1, STIM2, ORAI1 deﬁciencies [56–58,46]
Kaposi sarcoma Mutation of STIM1 [64]
Thalassemia STIM1 presence [61]
Systemic lupus erythematous STIM1 expression [62,79]
Cerebral vasospasm Higher levels of STIM1/ORAI1 [63]
Sjögren's syndrome Depressed levels of STIM1, STIM2. [65]
Multiple sclerosis STIM1/STIM2 deletion/depression. [66]
Other diseases and abnormal states
Hypertension, obesity, diabetes Overexpression of SGK1/STIM1 [67]
Acute lung injury/sepsis STIM1 expression [68]
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STIM1 and ORAI1 play a vital role in GBM and downregulation of both
proteins decreased the invasiveness of the cancer cells as compared to
the control [50]. Another study used three glioblastoma cell lines
(U251, U87 and U373). STIM1 function was lost in U251 cells and it
was seen that cell cycle arrest occurred in the GO/G1 phase conﬁrming
the role of STIM1 in GBM [51].
4.3. Immunology
Reviews of SOCE mediation of a variety of immune responses have
been published previously [52–56]. Here, we will discuss some of the
recent discoveries in this area. Needless to say, the immune system
has some of the most complicated Ca2+ signaling and functions since
immune cells need: to be activated into rapid proliferationwithout slip-
ping into a cancerous state; to bemotile on occasions tomove to sites of
inﬂammation; to act as suppressors such as suppressor T cells; to enter
apoptosis or NETosis when necessary for protection of the host against
pathogens or autoimmune reactions.
SOCE is the main Ca2+ ﬂux pathway in immune cells following any
antigen stimulation. One of the most important roles of the STIM
proteins in immune cells is the regulation of gene expression via
transcription factors like NFAT. Table 1 shows a few of the diseases
that are caused by immune cells due to abnormalities associated with
SOCE. Calcium ions function as second messengers in immune cells for
e.g. T cells, B cells, mast cells, NK cells, and dendritic cells. Patients
with inherited defects in SOCE due to mutations in genes of the ORAI
channel complex suffer from a severe form of immunodeﬁciency due
to defects in its function, but not the development of the cells. Ca2+
ions also regulate lymphocyte activation and differentiation among
other functions. It is seen that various protein tyrosine kinases, such as
Lck, Syk or zeta-chain-associated protein kinase 70 (ZAP-70), are acti-
vated by antigen binding in T and B cells which results in the phosphor-
ylation of proteins such as LAT, SLP-76, B cell linker protein (BLNK) and
Tec kinases IL-2-inducible T cell kinase (ITK) and Bruton's tyrosine
kinase (BTK). These can, in turn, result in the activation of PLC (in
T cells) or PLC 2 (in B cells) and hence the generation of inositol 1,4,5-triphosphate (IP3) which triggers Ca2+ release from the ER and subse-
quent SOCE [57]. STIM1 and STIM2 are both required for SOCE in
T cells and loss of function or null mutations in the human STIM1
gene stops Ca2+ inﬂux in T cells and causes immunodeﬁciencies in
affected patients. STIM1 and STIM2 deﬁciencies have been found in
a variety of immune system-related diseases. STIM1 deﬁciency was
studied in two patients with a homozygous R429C point mutation in
STIM1 which completely abolished SOCE in T cells. But it was found
that SOCE is not limiting for many aspects of these immune functions
but the combination of partially impaired T cell activation and other
effector functions with defects in other lymphocyte populations causes
immunodeﬁciency with immune dysregulation [58]. T cells and B cells
have differences in expression of STIM1 proteins. T cells have been
found to express up to 4 times the amount of STIM1 compared to B
cells [80]. Dendritic cells (DCs) are the antigen-presenting cells linking
innate and adaptive immunitywhosematuration andmigration depend
on alterations of cytosolic Ca2+ concentrations. Ca2+ entry, which is in
part accomplished by SOCE, is found to be partially mediated through
SGK3-dependent up-regulation of STIM2 expression [59].
Phagocytosis, which is one of the most important innate immune
responses to eliminate invading pathogenic agents, is accompanied by
the activation of antimicrobial enzymes, to allow for the production of
reactive oxygen species (ROS), leading to the destruction of ingested
microorganisms including granulocytes, dendritic cells, and macro-
phages, and possess speciﬁc receptorswhich, on triggering, engulf path-
ogenic material and secrete proinﬂammatorymediators involved in the
adaptive immune response. SOCE is required for phagocytosis via STIM/
ORAI1with the help of S100A8–A9 as a Ca2+ sensor [60]. SOCE deﬁcient
patients with mutations in STIM1 or ORAI1 genes are found to be sus-
ceptible to recurrent viral infections, potentially due to impaired
CD8(+) T cell function and elimination of virus infected cells such as
Epstein Barr virus (EBV) positive B cell lymphoma and human herpes
virus (HHV) 8 associated Kaposi sarcoma [46].
Cerebral vasospasm (CVS) which is a component of subarachnoid
hemorrhage (SAH), can be reduced by endothelin receptor antagonists.
Development of cerebral vasoplasm takes 5–7 days and elevatedmRNA
and protein expressions of ORAI1 and STIM1 were detected after SAH
and peaked on days 5 and 7 suggesting their role in the disease progres-
sion [63]. Kaposi sarcoma (KS) is exceedingly rare in children from the
Mediterranean Basin, despite high prevalence of human herpes virus-
8 (HHV-8) infection in this region. Whole-exome sequencing revealed
a homozygous splice-site mutation in STIM1, which led to the develop-
ment of lethal KS upon infection with HHV-8 [64].
Primary Sjögren's syndrome (pSS) is an autoimmune disease that
involves glands, tissue damage, and secretory defects in salivary and
exocrine glands. Mice with T-cells that have deleted STIM1 and STIM2
developed spontaneous and severe pSS-like autoimmune disease.
Sjögren's syndrome autoantibodies were also detected in the serum,
showing that deﬁciency of STIM1 and STIM2 proteins in T cells is asso-
ciated with salivary gland autoimmunopathy in pSS patients [65].
STIM1 and STIM2 have also shown roles in multiple sclerosis (MS).
T-cell-speciﬁc deletion of STIM1 or STIM2 in mice did not develop
experimental autoimmune encephalomyelitis (EAE), a mouse model
of MS, as they failed to produce the proinﬂammatory cytokines IL-17
and IFN-gamma [66]. Similarly, in another study, in which T cell func-
tion was assessed in mice that lacked STIM1 or STIM2 in a model
of myelin-oligodendrocyte glycoprotein (MOG) involvement in MS,
therewas less induction of EAE. STIM1 deﬁciency has been found to sig-
niﬁcantly impair generation of neuroantigen-speciﬁc T cell responses
with reduced Th1/Th17 responses, which resulted in no EAE in the
mice. Mice lacking STIM2 developed EAE, but to a lesser extent [17].
4.4. Other diseases and abnormal states
SOCE via STIM1 can also play a role in diseases such as hypertension,
obesity, diabetes, thrombosis, stroke, ﬁbrosing diseases, infertility and
2313S. Mukherjee, W.H. Brooks / Biochimica et Biophysica Acta 1843 (2014) 2307–2314tumor growth due to its activation depending on the expression of
serum-and-glucocorticoid-inducible kinase-1 (SGK1) which, though in
a low concentration at most times, is found to be elevated during
these pathological conditions and is known tomediate a variety of func-
tions including SOCE control [67].
SOCE may also be playing a role in acute lung injury which occurs
during sepsis and results fromactivation of innate immune cells and en-
dothelial cells by endotoxins, leading to systemic inﬂammation [68].
5. Conclusions
It is hoped that the reader has gained an appreciation for the impor-
tance of calcium dysregulation in a broad range of diseases. The impor-
tance, in particular, of STIM1 and STIM2 in calcium ﬂux cannot be
overstated since they are key early participants in SOCE aswell as affect-
ing other routes than just the ORAI channels. With this importance in
diseases, STIM1 and STIM2 are excellent targets for new therapeutics
with the caveat that there is still much to learn about these proteins
and their interactions. The 3D coordinates are available for the impor-
tant SOAR, EF hand and SAM domains so this can aid in computational
studies and virtual screening for drug candidates. There are numerous
questions to be answered but, foremost, would be: 1)What other inter-
actions do these proteins have? 2) What functions are served by the
N-terminal residues that have not been crystallized? Do those residues
participate in reinforcing calcium binding? Do those residues help
anchor STIM at some point? 3) What actions could be occurring with
the noted extracellular exposure of STIM1? Is this a means of rebinding
Ca2+ to inactivate STIM and then recycle it to the ER or does it provide
other functions for STIM1?We look forward to further developments in
this exciting area.
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